(NYSE: ZTS) Zoetis's forecast annual revenue growth rate of 1% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.88%.
Zoetis's revenue in 2026 is $9,517,000,000.On average, 21 Wall Street analysts forecast ZTS's revenue for 2026 to be $3,869,839,032,730, with the lowest ZTS revenue forecast at $3,657,855,324,904, and the highest ZTS revenue forecast at $4,235,541,920,500. On average, 20 Wall Street analysts forecast ZTS's revenue for 2027 to be $3,921,905,206,582, with the lowest ZTS revenue forecast at $3,584,301,523,748, and the highest ZTS revenue forecast at $4,411,575,174,952.
In 2028, ZTS is forecast to generate $4,070,665,703,302 in revenue, with the lowest revenue forecast at $3,654,962,759,690 and the highest revenue forecast at $4,595,459,677,842.